Project Grant R21AI190900
Award Date
7/16/25
Completion Date
6/30/27
Dollars Obligated
$234K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award of $3,317,325.00 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will support research to investigate the role of immune dysregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key objectives are to: 1) elucidate the relationships between immune deregulation, NGF dysmetabolism, and AD hallmarks in DS brain tissue and cell cultures; 2)...
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,483,910 to The Washington University in St. Louis to conduct research on novel genetic mechanisms underlying primary immune regulation disorders. The 5-year project, which commenced on April 8, 2025, aims to investigate three key areas: 1) epigenetic mechanisms leading to autosomal random monoallelic expression in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $936,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The 5-year grant, which commenced on August 12, 2024, will support research to elucidate the regulation and function of tissue-resident eosinophils in allergic microenvironments. The project aims to 1) target cell cycle machinery to manipulate eosinophil specialization, 2) delineate pre-...
This $5.2 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program, will fund research at the University of Colorado Denver to study neurovascular dysfunction in individuals with Down syndrome revealed by traumatic brain injury. Over three years, the collaborative multi-principal investigator team will establish how trisomy 21-related cellular defects and candidate genes exacerbate...
The National Institutes of Health (NIH) awarded a $2,507,286 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to investigate therapies for Down Syndrome Regression Disorder (DSRD). The 3-year grant, which commenced on September 1, 2024, supports a comparative clinical trial evaluating the safety and efficacy of three potential DSRD treatments: the benzodiazepine lorazepam, intravenous immunoglobulin (IVIG), and the JAK inhibitor tofacitinib. The project aims to advance...
This Project Grant award of $634,984 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the role of a specific B cell subset, termed BND2, in the rapid progression of type 1 diabetes (T1D) in young-onset patients. The primary objectives are to: 1) determine the mechanism by which these autoreactive B cells become activated and break anergy, 2) assess their potential to...
This Project Grant award, valued at $735,078, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports a 5-year research project to investigate the molecular mechanisms of innate immune memory in humans, with a focus on understanding the epigenetic determinants that enable long-lasting "trained immunity" in myeloid and lymphoid progenitor cells. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $152,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The grant, titled "Synaptopodin and Its Role in Shigella flexneri Intercellular Spread," will fund research to investigate the molecular mechanisms by which the protein synaptopodin promotes the ability of the Shigella bacteria to spread between cells, a critical process for...
This $225,953 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research aims to define the characteristics of human B cells that specifically target foreign glycans, known as xenoglycans. The funded research will use antigen-specific tetramers to identify and isolate distinct populations of xenoglycan-reactive B cells and compare their phenotypic and functional properties to protein-reactive B cells....